CTXR vs NVS
Citius Pharmaceuticals Inc (CTXR) versus NVS (NVS) — a side-by-side from cached financials, not a winner call.
Citius Pharmaceuticals Inc (CTXR) is a biotechnology company listed on US.
NVS (NVS) common stock.
Latest reported CTXR revenue for 2026-06-30 was $7.1M. Net income was -$49.4M. Revenue was up 26.6% from 2026-03-31 to 2026-06-30. CTXR currently screens at market cap $13.4M.
NVS does not have a complete income-statement cache yet.
CTXR currently screens at market cap $13.4M. NVS currently screens at market cap $0.
Not investment advice. Open the CTXR and NVS stock pages for the full models.
Not investment advice.